Hanan Mohamed Nomeir (Hanan M Nomeir)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 11

Top Topics

Disease Activity

Positron Emission Tomography

Respiratory Syndrome Coronavirus

Rheumatoid Arthritis Patients

Top Venues

Clinical rheumatology

This page only lists publications with an associated author ORCID identifier.

Publications

Azhar M Nomair, Abeer Ali Abdelati, Fatma I Dwedar, Rehab Elnemr, Yasmine N Kamel, Hanan Mohamed Nomeir
The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients. Clinical rheumatology 43 (3) (2024)
Azhar M Nomair, Abeer Ali Abdelati, Fatma I Dwedar, Rehab Elnemr, Yasmine N Kamel, Hanan Mohamed Nomeir
The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients. Clinical rheumatology 43 (3) (2024)
Azhar M Nomair, Abeer Ali Abdelati, Fatma I Dwedar, Rehab Elnemr, Yasmine N Kamel, Hanan Mohamed Nomeir
The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients. Clinical rheumatology 43 (3) (2024)
Azhar M Nomair, Abeer Ali Abdelati, Fatma I Dwedar, Rehab Elnemr, Yasmine N Kamel, Hanan Mohamed Nomeir
The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients. Clinical rheumatology (2024)
Azhar M Nomair, Abeer Ali Abdelati, Fatma I Dwedar, Rehab Elnemr, Yasmine N Kamel, Hanan Mohamed Nomeir
The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients. Clinical rheumatology 43 (3) (2024)
Azhar M Nomair, Abeer Ali Abdelati, Fatma I Dwedar, Rehab Elnemr, Yasmine N Kamel, Hanan Mohamed Nomeir
The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients. Clinical rheumatology 43 (3) (2024)
Manal Mohamed Saber, Azhar Mohamed Nomair, Ashraf M Osman, Hanan Mohamed Nomeir, Naglaa M Farag
Endothelial Monocyte-Activating Polypeptide-II Is an Indicator of Severity and Mortality in COVID-19 Patients. Vaccines 10 (12) (2022)
Manal Mohamed Saber, Azhar Mohamed Nomair, Ashraf M Osman, Hanan Mohamed Nomeir, Naglaa M Farag
Endothelial Monocyte-Activating Polypeptide-II Is an Indicator of Severity and Mortality in COVID-19 Patients. Vaccines 10 (12) (2022)
Manal Mohamed Saber, Azhar Mohamed Nomair, Ashraf M Osman, Hanan Mohamed Nomeir, Naglaa M Farag
Endothelial Monocyte-Activating Polypeptide-II Is an Indicator of Severity and Mortality in COVID-19 Patients. Vaccines 10 (12) (2022)
Manal Mohamed Saber, Azhar Mohamed Nomair, Ashraf M Osman, Hanan Mohamed Nomeir, Naglaa M Farag
Endothelial Monocyte-Activating Polypeptide-II Is an Indicator of Severity and Mortality in COVID-19 Patients. Vaccines 10 (12) (2022)
Manal Mohamed Saber, Azhar Mohamed Nomair, Ashraf M Osman, Hanan Mohamed Nomeir, Naglaa M Farag
Endothelial Monocyte-Activating Polypeptide-II Is an Indicator of Severity and Mortality in COVID-19 Patients. Vaccines 10 (12) (2022)